Selected article for: "decrease lymphocyte count and lymphocyte count"
Author: Han, Dan; Peng, Chunfen; Meng, Rui; Yao, Jing; Zhou, Qiong; Xiao, Yong; Ma, Hong
Title: Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities
  • Cord-id: a67erfi0
  • Document date: 2020_11_24
    • ID: a67erfi0
    Snippet: COVID-19 exhibits both variability and rapid progression, particularly in patients with comorbidities such as diabetes, hypertension or cancer. To determine how these underlying disorders exacerbate pneumonia in COVID-19, we evaluated 79 patients with severe COVID-19 and grouped them according to whether or not they had comorbidities. Clinical information, laboratory examinations, immunological function, and treatment outcomes were retrospectively analyzed. Our study revealed that severe COVID-1
    Document: COVID-19 exhibits both variability and rapid progression, particularly in patients with comorbidities such as diabetes, hypertension or cancer. To determine how these underlying disorders exacerbate pneumonia in COVID-19, we evaluated 79 patients with severe COVID-19 and grouped them according to whether or not they had comorbidities. Clinical information, laboratory examinations, immunological function, and treatment outcomes were retrospectively analyzed. Our study revealed that severe COVID-19 patients with comorbidities had higher levels of inflammatory indices, including blood interferon-γ, interleukin (IL)-6 and c-reactive protein levels as well as the erythrocyte sedimentation rate. These were accompanied by lymphopenia, hypokalemia, hypoalbuminemia, a decrease in either CD4+ T cells or lymphocyte count, and coagulation disorders, which were closely related to poor prognosis. Patients with comorbidities also had longer disease remission times (27 ± 6.7 days) than those without comorbidities (20 ± 6.5 days). Cox multivariate analysis indicated that glucocorticoid therapy and IL-6 were independent prognostic factors. Our findings suggest that coexisting comorbidities aggravate COVID-19 through the excessive release of inflammatory factors and that glucocorticoid therapy may be beneficial.

    Search related documents:
    Co phrase search for related documents
    • abnormal coagulation and acid nucleic: 1, 2
    • abnormal coagulation and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5
    • abnormal coagulation and admission patient: 1, 2, 3
    • abnormal coagulation and lung tissue: 1
    • abnormal coagulation and lymphocyte count: 1, 2
    • acid detection and acute sars cov respiratory syndrome cov: 1, 2, 3, 4
    • acid detection and admission patient: 1, 2, 3
    • acid detection and lung tissue: 1, 2, 3
    • acid detection and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acid nucleic and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid nucleic and acute sars cov respiratory syndrome cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acid nucleic and admission patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acid nucleic and log rank test kaplan meier method: 1
    • acid nucleic and long hospital stay: 1
    • acid nucleic and lung lesion: 1, 2, 3, 4, 5, 6
    • acid nucleic and lung lesion absorption: 1, 2
    • acid nucleic and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acid nucleic and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
    • acid nucleic and lymphocyte count level: 1, 2, 3